Bortezomib, Dexamethasone, and Lenalidomide with or without Elotuzumab in Treating Patients with Newly Diagnosed High-Risk Multiple Myeloma

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Basic Trial Information

PhaseTypeAgeTrial IDs
Phase II, Phase ITreatment18 and overS1211
NCI-2012-01998, CDR0000738512, PS1211_A12PAMDREVW01, SWOG-S1211, NCT01668719

Trial Description

Summary

This partially randomized phase I/II trial studies the side effects and best dose of elotuzumab and to see how well it works when given together with lenalidomide, bortezomib, and dexamethasone in treating patients with newly diagnosed multiple myeloma that is likely to recur (come back), or spread (high-risk). Lenalidomide and bortezomib may stop the growth of multiple myeloma by blocking blood flow to the tumor. Also, bortezomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as lenalidomide and dexamethasone, also work in different ways to kill cancer cells, by stopping them from dividing, or by stopping them from spreading. Giving elotuzumab together with lenalidomide, bortezomib, and dexamethasone may be a better way to block cancer growth.

Further Study Information

PRIMARY OBJECTIVES:

I. To determine the appropriate Phase II dose of elotuzumab to use in combination with lenalidomide, bortezomib, and dexamethasone for patients with multiple myeloma. (Phase I)

II. To assess whether incorporation of the novel agent elotuzumab into the treatment algorithm of high-risk multiple myeloma (HRMM) will improve progression-free survival (PFS). (Phase II)

III. To estimate the frequency and severity of toxicities of this treatment strategy in this patient population. (Phase II)

OUTLINE: This is a phase I, dose-escalation study of elotuzumab, followed by a phase II, randomized study.

PHASE I:

INDUCTION: Patients receive bortezomib subcutaneously (SC) or intravenously (IV) on days 1, 4, 8, and 11; lenalidomide orally (PO) once daily (QD) on days 1-14; and dexamethasone PO or IV on days 1, 2, 4, 5, 8, 9, 11, and 12 (and on day 15 of courses 1 and 2 only). Patients also receive elotuzumab IV on days 1, 8, and 15 of courses 1 and 2 and on days 1 and 11 of courses 3-8. Treatment repeats every 21 days for 8 courses in the absence of disease progression or unacceptable toxicity.

MAINTENANCE: Patients receive bortezomib SC or IV on days 1, 8, and 15; lenalidomide PO QD on days 1-21; dexamethasone PO on days 1, 8, and 15; and elotuzumab IV on days 1 and 15. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.

PHASE II: Patients are randomized to 1 of 2 treatment arms.

ARM I:

INDUCTION: Patients receive bortezomib SC or IV on days 1, 4, 8, and 11; lenalidomide PO QD on days 1-14; and dexamethasone PO or IV on days 1, 2, 4, 5, 8, 9, 11, and 12. Treatment repeats every 21 days for 8 courses in the absence of disease progression or unacceptable toxicity (patients who received a course of chemotherapy prior to registration will begin protocol treatment with course 2 and receive a total of 7 courses of protocol therapy).

MAINTENANCE: Patients receive bortezomib SC or IV on days 1, 8, and 15; lenalidomide PO QD on days 1-21; and dexamethasone PO on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

ARM II:

INDUCTION: Patients receive bortezomib, lenalidomide, and dexamethasone as in Arm I. Patients also receive elotuzumab IV on days 1, 8, and 15 of courses 1 and 2 and on days 1 and 11 of courses 3-8. Treatment repeats every 21 days for 8 courses in the absence of disease progression or unacceptable toxicity.

MAINTENANCE: Patients receive bortezomib, lenalidomide, and dexamethasone as in Arm I. Patients also receive elotuzumab IV on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up every 3 months for up to 6 years.

Eligibility Criteria

Inclusion Criteria:

Patients must have baseline skeletal survey (whole body x-ray) to document lytic lesions, osteopenia or compression fracture

Patients must not have any psychiatric illness that could potentially interfere with the completion of treatment according to this protocol

Patients must have history and physical examination within 28 days prior to registration

Uncontrolled blood pressure and hypertension: systolic blood pressure (SBP) > 140 mm Hg or diastolic blood pressure (DBP) > 90 mm Hg within 14 days prior to registration; patients are permitted to be receiving multiple anti-hypertensive medications (unless otherwise indicated in the study); all blood pressure measurements within the 14 days prior to registration and on day 1 of cycle 1 must be SBP =< 140 and DBP =< 90; an exception can be made by a healthcare provider for a patient with a single blood pressure elevation who upon rechecking has a normal blood pressure

Uncontrolled diabetes: a glycated hemoglobin (Hg A1C) > 7% within 14 days prior to registration; the same criterion will be used in patients with confirmed diagnosis of diabetes mellitus who have been on a stable dietary or therapeutic regimen for this condition in the last three months

Patients must not have clinically significant illness including uncontrolled, active infection requiring intravenous antibiotics, New York Heart Association (NYHA) class III or class IV heart failure, unstable angina pectoris, myocardial infarction within the past 6 months, uncontrolled >= grade 3 cardiac arrhythmias, uncontrolled hypertension, or uncontrolled diabetes mellitus; patients must have undergone an electrocardiogram (EKG) within 28 days prior to registration

Patients must not have POEMS syndrome (plasma cell dyscrasia with polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes)

Patients with known hepatitis B or hepatitis C infection may be eligible providing they have viral load < 800,000 IU/L within 28 days prior to registration

Patients must have Zubrod performance status =< 2

Patients who are known to be human immunodeficiency virus positive (HIV+) are eligible providing they meet all of the following additional criteria within 28 days prior to registration:

Cluster of differentiation (CD)4 cells >= 500/mm^3

Viral load of < 50 copies HIV messenger ribonucleic acid (mRNA)/mm^3 if on combination antiretroviral therapy (cART) or < 25,000 copies HIV mRNA if not on cART

No zidovudine or stavudine as part of cART

Patients who are HIV+ and do not meet all of these criteria are not eligible for this study

Patients must not have active involvement of the central nervous system (CNS) with MM (by clinical evaluation); patients with documentation of, or clinical signs or symptoms consistent with, CNS involvement of MM must have a lumbar puncture that is negative for CNS involvement of MM; the lumbar puncture must be completed within 14 days prior to registration; patients with no previous history of documented CNS involvement and with no clinical signs or symptoms consistent with CNS involvement are not required to have completed a lumbar puncture prior to registration; note that monitoring of CNS involvement and treatment with intrathecal therapy is recommended during protocol treatment

Creatinine clearance (CrCL) >= 30 mL/min, measured by a 24-hour urine collection or estimated by the Cockcroft and Gault formula within 14 days prior to registration

Serum glutamic oxaloacetic transaminase (SGOT)/aspartate aminotransferase (AST) and serum glutamate pyruvate transaminase (SGPT)/alanine aminotransferase (ALT) =< 2.5 x IULN

Total bilirubin =< 1.5 x institutional upper limit of normal (IULN)

Platelet count >= 70,000 cells/mm^3 for patients who have bone marrow plasmacytosis < 50%; or >= 50,000 cells/mm^3 for patients who have bone marrow plasmacytosis of >= 50%

Patients on the Phase I portion may not have received ANY prior chemotherapy; patients on the Phase II portion may have received one prior cycle of any non-investigational chemotherapy; prior chemotherapy must have been completed within 56 days prior to registration and all toxicities must have resolved to =< grade 1; patients on either portion may have received prior treatment with dexamethasone, providing total number of days of treatment was =< 14 days and total treatment dose was =< 360 mg

For the Phase II portion only, patients must have high-risk MM based on one or more of the following criteria at the time of initial diagnosis (prior to any chemotherapy):

Poor-risk genomic signature according to the University of Arkansas 70-gene model (available clinically as myeloma prognostic risk score [MyPRS] score, Signal Genetics, Inc) AND/OR

Translocation (14;16), and/or translocation (14;20), and/or deletion (17p) by fluorescence in-situ hybridization (FISH) or cytogenetics AND/OR

Primary plasma cell leukemia (defined by either >= 2,000 plasma cells/mL of peripheral blood, or 20% on a manual differential count) AND/OR

Serum lactate dehydrogenase (LDH) >= 2 x institutional upper limit of normal (IULN) AND/OR

1q21 amplification by FISH analysis AND/OR

High risk by the SKY92 signature

As a part of the Oncology Patient Enrollment Network (OPEN) registration process the treating institution's identity is provided in order to ensure that the current (within 365 days) date of institutional review board approval for this study has been entered in the system

Patients or their legally authorized representative must be informed of the investigational nature of this study and must sign and give written informed consent in accordance with institutional and federal guidelines

Patients must be registered to the mandatory Revlimid Risk Evaluation and Mitigation Strategy (REMS)™ program and must be willing and able to comply with the requirements of the Revlimid REMS™ program

Patients must be offered participation in banking of specimens for future research; with the patient’s consent, specimens (serum and bone marrow biopsy core) must be submitted to the repository; patient consent must be obtained before specimens are submitted

No other prior malignancy is allowed except for the following: adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, adequately treated stage I or II cancer from which the patient is currently in complete remission, or any other cancer from which the patient has been disease free for five years

Females of childbearing potential (FCBP) must have a negative serum or urine pregnancy test with a sensitivity of at least 25 mIU/mL within 10 – 14 days prior to registration; (Note: that pregnancy testing is also required within 24 hours prior to treatment on cycle 1, day 1); furthermore, they must either commit to continued abstinence from heterosexual intercourse or begin TWO acceptable methods of birth control: one highly effective method and one additional effective method AT THE SAME TIME, at least 28 days before starting lenalidomide; FCBP must also agree to ongoing pregnancy testing; men must agree to use a latex condom during sexual contact with a FCBP, even if they have had a successful vasectomy; a FCBP is a sexually mature woman who: 1) has not undergone a hysterectomy or bilateral oophorectomy; or 2) has not been naturally postmenopausal for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months)

Absolute neutrophil count (ANC) >= 1,000 cells/mm^3 without growth factor support

Patients may have received prior radiotherapy for symptomatic localized bone lesions or impending spinal cord compression only; radiotherapy must be completed at least 14 days prior to registration and all toxicities must have resolved to =< grade 1

Patients must have measurable disease within 28 days prior to registration (or prior to initiation of first induction course for patients with prior therapy)

Patients with non-secretory MM or known amyloidosis are not eligible

Patients must have newly diagnosed active multiple myeloma (MM)

Trial Contact Information

Trial Lead Organizations / Sponsors / Collaborators

SWOG

  • National Cancer Institute
Saad Zafar Usmani, Principal Investigator

Trial Sites

U.S.A.

Alaska
Anchorage

Anchorage Oncology Centre

Alison Katherine Conlin
Ph: 503-215-6412

Alison Katherine Conlin
Principal Investigator

Katmai Oncology Group

Alison Katherine Conlin
Ph: 503-215-6412

Alison Katherine Conlin
Principal Investigator

Providence Alaska Medical Center

Alison Katherine Conlin
Ph: 503-215-6412

Alison Katherine Conlin
Principal Investigator

California
Duarte

City of Hope Comprehensive Cancer Center

Michael A. Rosenzweig
Ph: 800-826-4673
Email: becomingapatient@coh.org

Michael A. Rosenzweig
Principal Investigator

Los Angeles

Los Angeles County-USC Medical Center

Kevin R. Kelly
Ph: 323-865-0451

Kevin R. Kelly
Principal Investigator

USC / Norris Comprehensive Cancer Center

Kevin R. Kelly
Ph: 323-865-0451

Kevin R. Kelly
Principal Investigator

Connecticut
Hartford

Saint Francis Hospital and Medical Center

Christopher M. Reynolds
Ph: 734-712-4673

Christopher M. Reynolds
Principal Investigator

New Britain

The Hospital of Central Connecticut

Brian J. Byrne
Ph: 860-224-5660

Brian J. Byrne
Principal Investigator

Delaware
Lewes

Beebe Medical Center

Stephen Scott Grubbs
Ph: 302-733-6227

Stephen Scott Grubbs
Principal Investigator

Newark

Christiana Care Health System-Christiana Hospital

Stephen Scott Grubbs
Ph: 302-733-6227

Stephen Scott Grubbs
Principal Investigator

Christiana Gynecologic Oncology LLC

Stephen Scott Grubbs
Ph: 302-733-6227

Stephen Scott Grubbs
Principal Investigator

Delaware Clinical and Laboratory Physicians PA

Stephen Scott Grubbs
Ph: 302-733-6227

Stephen Scott Grubbs
Principal Investigator

Helen F Graham Cancer Center

Stephen Scott Grubbs
Ph: 302-733-6227

Stephen Scott Grubbs
Principal Investigator

Medical Oncology Hematology Consultants PA

Stephen Scott Grubbs
Ph: 302-733-6227

Stephen Scott Grubbs
Principal Investigator

Regional Hematology and Oncology PA

Stephen Scott Grubbs
Ph: 302-733-6227

Stephen Scott Grubbs
Principal Investigator

Rehoboth Beach

Beebe Health Campus

Stephen Scott Grubbs
Ph: 302-733-6227

Stephen Scott Grubbs
Principal Investigator

Seaford

Nanticoke Memorial Hospital

Stephen Scott Grubbs
Ph: 302-733-6227

Stephen Scott Grubbs
Principal Investigator

Wilmington

Christiana Care Health System-Wilmington Hospital

Stephen Scott Grubbs
Ph: 302-733-6227

Stephen Scott Grubbs
Principal Investigator

Florida
Jacksonville

Mayo Clinic in Florida

Ronald S. Go
Ph: 507-538-7623

Ronald S. Go
Principal Investigator

Hawaii
Aiea

Oncare Hawaii Inc-Pali Momi

Jeffrey L. Berenberg
Ph: 808-586-2979

Jeffrey L. Berenberg
Principal Investigator

Pali Momi Medical Center

Jeffrey L. Berenberg
Ph: 808-586-2979

Jeffrey L. Berenberg
Principal Investigator

Honolulu

Kapiolani Medical Center for Women and Children

Jeffrey L. Berenberg
Ph: 808-586-2979

Jeffrey L. Berenberg
Principal Investigator

Oncare Hawaii Inc-Kuakini

Jeffrey L. Berenberg
Ph: 808-586-2979

Jeffrey L. Berenberg
Principal Investigator

Oncare Hawaii Inc-POB II

Jeffrey L. Berenberg
Ph: 808-586-2979

Jeffrey L. Berenberg
Principal Investigator

OnCare Hawaii-Liliha

Jeffrey L. Berenberg
Ph: 808-586-2979

Jeffrey L. Berenberg
Principal Investigator

Queen's Medical Center

Jeffrey L. Berenberg
Ph: 808-586-2979

Jeffrey L. Berenberg
Principal Investigator

Straub Clinic and Hospital

Jeffrey L. Berenberg
Ph: 808-586-2979

Jeffrey L. Berenberg
Principal Investigator

University of Hawaii Cancer Center

Jeffrey L. Berenberg
Ph: 808-586-2979

Jeffrey L. Berenberg
Principal Investigator

Lihue

Wilcox Memorial Hospital and Kauai Medical Clinic

Jeffrey L. Berenberg
Ph: 808-586-2979

Jeffrey L. Berenberg
Principal Investigator

Idaho
Boise

Saint Alphonsus Cancer Care Center-Boise

Christopher M. Reynolds
Ph: 734-712-4673

Christopher M. Reynolds
Principal Investigator

Illinois
Bloomington

Illinois CancerCare-Bloomington

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Canton

Illinois CancerCare-Canton

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Carbondale

Memorial Hospital of Carbondale

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Carthage

Illinois CancerCare-Carthage

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Centralia

Centralia Oncology Clinic

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Decatur

Cancer Care Center of Decatur

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Decatur Memorial Hospital

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Effingham

Crossroads Cancer Center

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Eureka

Illinois CancerCare-Eureka

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Galesburg

Illinois CancerCare Galesburg

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Western Illinois Cancer Treatment Center

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Harvey

Ingalls Memorial Hospital

Mark Farrell Kozloff
Ph: 708-915-4673
Email: clinicaltrials@ingalls.org

Mark Farrell Kozloff
Principal Investigator

Kewanee

Illinois CancerCare-Kewanee Clinic

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Macomb

Illinois CancerCare-Macomb

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Maywood

Loyola University Medical Center

Kevin Patrick Barton
Ph: 708-226-4357

Kevin Patrick Barton
Principal Investigator

Moline

Garneau, Stewart C MD (UIA Investigator)

David Martens Spector
Ph: 309-779-4200

David Martens Spector
Principal Investigator

Spector, David MD (UIA Investigator)

David Martens Spector
Ph: 309-779-4200

David Martens Spector
Principal Investigator

Trinity Medical Center

David Martens Spector
Ph: 309-779-4200

David Martens Spector
Principal Investigator

Mount Vernon

Good Samaritan Regional Health Center

Jay W. Carlson
Ph: 800-821-7532

Jay W. Carlson
Principal Investigator

Ottawa

Illinois CancerCare-Ottawa Clinic

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Radiation Oncology of Northern Illinois

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Pekin

Illinois CancerCare-Pekin

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Pekin Cancer Treatment Center

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Peoria

Illinois CancerCare-Peoria

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Methodist Medical Center of Illinois

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Peru

Illinois CancerCare-Peru

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Valley Radiation Oncology

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Princeton

Illinois CancerCare-Princeton

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Springfield

Central Illinois Hematology Oncology Center

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Memorial Medical Center

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Southern Illinois University School of Medicine

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Springfield Clinic

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Swansea

Cancer Care Specialists of Illinois-Swansea

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Indiana
Richmond

Reid Hospital and Health Care Services

Howard M. Gross
Ph: 937-775-1350

Howard M. Gross
Principal Investigator

Iowa
Ames

Mary Greeley Medical Center

Joseph James Merchant
Ph: 515-239-2621

Joseph James Merchant
Principal Investigator

McFarland Clinic PC-William R Bliss Cancer Center

Joseph James Merchant
Ph: 515-239-2621

Joseph James Merchant
Principal Investigator

Bettendorf

Constantinou, Costas L MD (UIA Investigator)

David Martens Spector
Ph: 309-779-4200

David Martens Spector
Principal Investigator

Boone

McFarland Clinic PC-Boone

Joseph James Merchant
Ph: 515-239-2621

Joseph James Merchant
Principal Investigator

Fort Dodge

McFarland Clinic PC-Trinity Cancer Center

Joseph James Merchant
Ph: 515-239-2621

Joseph James Merchant
Principal Investigator

Jefferson

McFarland Clinic PC-Jefferson

Joseph James Merchant
Ph: 515-239-2621

Joseph James Merchant
Principal Investigator

Marshalltown

McFarland Clinic PC-Marshalltown

Joseph James Merchant
Ph: 515-239-2621

Joseph James Merchant
Principal Investigator

Sioux City

Siouxland Regional Cancer Center

Donald B. Wender
Ph: 712-252-0088

Donald B. Wender
Principal Investigator

Kansas
Emporia

Newman Regional Health

Peter J. Van Veldhuizen
Ph: 800-525-1483

Peter J. Van Veldhuizen
Principal Investigator

Garden City

Saint Catherine Hospital

Peter J. Van Veldhuizen
Ph: 800-525-1483

Peter J. Van Veldhuizen
Principal Investigator

Great Bend

Saint Rose Ambulatory and Surgery Center

Peter J. Van Veldhuizen
Ph: 800-525-1483

Peter J. Van Veldhuizen
Principal Investigator

Hays

Hays Medical Center

Peter J. Van Veldhuizen
Ph: 800-525-1483

Peter J. Van Veldhuizen
Principal Investigator

Kansas City

Kansas City Cancer Center-West

Peter J. Van Veldhuizen
Ph: 800-525-1483

Peter J. Van Veldhuizen
Principal Investigator

University of Kansas Cancer Center

Peter J. Van Veldhuizen
Ph: 800-525-1483

Peter J. Van Veldhuizen
Principal Investigator

Lawrence

Lawrence Memorial Hospital

Shaker R. Dakhil
Ph: 316-262-4467

Shaker R. Dakhil
Principal Investigator

Olathe

Olathe Medical Center

Peter J. Van Veldhuizen
Ph: 800-525-1483

Peter J. Van Veldhuizen
Principal Investigator

Overland Park

Kansas City Cancer Centers-Southwest

Peter J. Van Veldhuizen
Ph: 800-525-1483

Peter J. Van Veldhuizen
Principal Investigator

Menorah Medical Center

Rakesh Gaur
Ph: 913-948-5588
Email: aroland@kccop.org

Rakesh Gaur
Principal Investigator

Saint Luke's South Hospital

Rakesh Gaur
Ph: 913-948-5588
Email: aroland@kccop.org

Rakesh Gaur
Principal Investigator

Pittsburg

Via Christi Hospital-Pittsburg

Peter J. Van Veldhuizen
Ph: 800-525-1483

Peter J. Van Veldhuizen
Principal Investigator

Salina

Salina Regional Health Center

Peter J. Van Veldhuizen
Ph: 800-525-1483

Peter J. Van Veldhuizen
Principal Investigator

Topeka

Saint Francis Hospital and Medical Center - Topeka

Peter J. Van Veldhuizen
Ph: 800-525-1483

Peter J. Van Veldhuizen
Principal Investigator

Wichita

Wesley Medical Center

Shaker R. Dakhil
Ph: 316-262-4467

Shaker R. Dakhil
Principal Investigator

Kentucky
Crestview Hills

Oncology Hematology Care Inc-Crestview

Howard M. Gross
Ph: 937-775-1350

Howard M. Gross
Principal Investigator

Louisiana
Baton Rouge

Hematology/Oncology Clinic LLP

Hana F. Safah
Ph: 504-988-6121

Hana F. Safah
Principal Investigator

Marrero

West Jefferson Medical Center

Hana F. Safah
Ph: 504-988-6121

Hana F. Safah
Principal Investigator

New Orleans

Tulane University Health Sciences Center

Hana F. Safah
Ph: 504-988-6121

Hana F. Safah
Principal Investigator

Maryland
Baltimore

Sinai Hospital of Baltimore

Roberto F. Martinez
Ph: 410-601-6120
Email: pridgely@lifebridgehealth.org

Roberto F. Martinez
Principal Investigator

Michigan
Adrian

Hickman Cancer Center

Rex B. Mowat
Ph: 800-444-3561

Rex B. Mowat
Principal Investigator

Ann Arbor

Saint Joseph Mercy Hospital

Christopher M. Reynolds
Ph: 734-712-4673

Christopher M. Reynolds
Principal Investigator

Battle Creek

Bronson Battle Creek

Gilbert D.A. Padula
Ph: 616-685-5225
Email: connie.szczepanek@grcop.org

Gilbert D.A. Padula
Principal Investigator

Dearborn

Oakwood Hospital and Medical Center

Christopher M. Reynolds
Ph: 734-712-4673

Christopher M. Reynolds
Principal Investigator

Detroit

Barbara Ann Karmanos Cancer Institute

Jeffrey Allan Zonder
Email: zonderj@karmanos.org

Jeffrey Allan Zonder
Principal Investigator

Saint John Hospital and Medical Center

Christopher M. Reynolds
Ph: 734-712-4673

Christopher M. Reynolds
Principal Investigator

Wayne State University/Karmanos Cancer Institute

Jeffrey Allan Zonder
Ph: 313-576-9363

Jeffrey Allan Zonder
Principal Investigator

Escanaba

Green Bay Oncology - Escanaba

Matthew L. Ryan
Ph: 800-432-6049

Matthew L. Ryan
Principal Investigator

Farmington Hills

Weisberg Cancer Treatment Center

Jeffrey Allan Zonder
Ph: 313-576-9363

Jeffrey Allan Zonder
Principal Investigator

Flint

Genesys Hurley Cancer Institute

Christopher M. Reynolds
Ph: 734-712-4673

Christopher M. Reynolds
Principal Investigator

Hurley Medical Center

Christopher M. Reynolds
Ph: 734-712-4673

Christopher M. Reynolds
Principal Investigator

Grand Rapids

Mercy Health Saint Mary's

Gilbert D.A. Padula
Ph: 616-685-5225
Email: connie.szczepanek@grcop.org

Gilbert D.A. Padula
Principal Investigator

Spectrum Health at Butterworth Campus

Gilbert D.A. Padula
Ph: 616-685-5225
Email: connie.szczepanek@grcop.org

Gilbert D.A. Padula
Principal Investigator

Iron Mountain

Green Bay Oncology - Iron Mountain

Matthew L. Ryan
Ph: 800-432-6049

Matthew L. Ryan
Principal Investigator

Jackson

Allegiance Health

Christopher M. Reynolds
Ph: 734-712-4673

Christopher M. Reynolds
Principal Investigator

Kalamazoo

Borgess Medical Center

Sunil Nagpal
Ph: 269-373-7458

Sunil Nagpal
Principal Investigator

Bronson Methodist Hospital

Sunil Nagpal
Ph: 269-373-7458

Sunil Nagpal
Principal Investigator

West Michigan Cancer Center

Sunil Nagpal
Ph: 269-373-7458

Sunil Nagpal
Principal Investigator

Lansing

Sparrow Hospital

Christopher M. Reynolds
Ph: 734-712-4673

Christopher M. Reynolds
Principal Investigator

Livonia

Saint Mary Mercy Hospital

Christopher M. Reynolds
Ph: 734-712-4673

Christopher M. Reynolds
Principal Investigator

Monroe

Toledo Clinic Cancer Centers-Monroe

Rex B. Mowat
Ph: 800-444-3561

Rex B. Mowat
Principal Investigator

Muskegon

Mercy Health Mercy Campus

Gilbert D.A. Padula
Ph: 616-685-5225
Email: connie.szczepanek@grcop.org

Gilbert D.A. Padula
Principal Investigator

Niles

Lakeland Community Hospital

Gilbert D.A. Padula
Ph: 616-685-5225
Email: connie.szczepanek@grcop.org

Gilbert D.A. Padula
Principal Investigator

Pontiac

Saint Joseph Mercy Oakland

Christopher M. Reynolds
Ph: 734-712-4673

Christopher M. Reynolds
Principal Investigator

Port Huron

Saint Joseph Mercy Port Huron

Christopher M. Reynolds
Ph: 734-712-4673

Christopher M. Reynolds
Principal Investigator

Reed City

Spectrum Health Reed City Hospital

Gilbert D.A. Padula
Ph: 616-685-5225
Email: connie.szczepanek@grcop.org

Gilbert D.A. Padula
Principal Investigator

Saginaw

Saint Mary's of Michigan

Christopher M. Reynolds
Ph: 734-712-4673

Christopher M. Reynolds
Principal Investigator

Saint Joseph

Marie Yeager Cancer Center

Gilbert D.A. Padula
Ph: 616-685-5225
Email: connie.szczepanek@grcop.org

Gilbert D.A. Padula
Principal Investigator

Southfield

Providence Hospital

Andrew Aaron Muskovitz
Ph: 248-849-5337
Email: jaswinder.grewal@stjohn.org

Andrew Aaron Muskovitz
Principal Investigator

St. Joseph

Lakeland Hospital

Gilbert D.A. Padula
Ph: 616-685-5225
Email: connie.szczepanek@grcop.org

Gilbert D.A. Padula
Principal Investigator

Traverse City

Munson Medical Center

Gilbert D.A. Padula
Ph: 616-685-5225
Email: connie.szczepanek@grcop.org

Gilbert D.A. Padula
Principal Investigator

Warren

Saint John Macomb-Oakland Hospital

Christopher M. Reynolds
Ph: 734-712-4673

Christopher M. Reynolds
Principal Investigator

Minnesota
Bemidji

Sanford Clinic North-Bemidgi

Preston D. Steen
Ph: 701-234-6161

Preston D. Steen
Principal Investigator

Burnsville

Fairview Ridges Hospital

Patrick James Flynn
Ph: 952-993-1517
Email: MMCCOP@parknicollet.com

Patrick James Flynn
Principal Investigator

Coon Rapids

Mercy Hospital

Patrick James Flynn
Ph: 952-993-1517
Email: MMCCOP@parknicollet.com

Patrick James Flynn
Principal Investigator

Duluth

Essentia Health Cancer Center

Bret E.B. Friday
Ph: 888-203-7267

Bret E.B. Friday
Principal Investigator

Essentia Health Saint Mary's Medical Center

Bret E.B. Friday
Ph: 888-203-7267

Bret E.B. Friday
Principal Investigator

Miller-Dwan Hospital

Bret E.B. Friday
Ph: 888-203-7267

Bret E.B. Friday
Principal Investigator

Edina

Fairview-Southdale Hospital

Patrick James Flynn
Ph: 952-993-1517
Email: MMCCOP@parknicollet.com

Patrick James Flynn
Principal Investigator

Fridley

Unity Hospital

Patrick James Flynn
Ph: 952-993-1517
Email: MMCCOP@parknicollet.com

Patrick James Flynn
Principal Investigator

Hutchinson

Hutchinson Area Health Care

Patrick James Flynn
Ph: 952-993-1517
Email: MMCCOP@parknicollet.com

Patrick James Flynn
Principal Investigator

Maplewood

Minnesota Oncology Hematology PA-Maplewood

Patrick James Flynn
Ph: 952-993-1517
Email: MMCCOP@parknicollet.com

Patrick James Flynn
Principal Investigator

Saint John's Hospital - Healtheast

Patrick James Flynn
Ph: 952-993-1517
Email: MMCCOP@parknicollet.com

Patrick James Flynn
Principal Investigator

Minneapolis

Abbott-Northwestern Hospital

Patrick James Flynn
Ph: 952-993-1517
Email: MMCCOP@parknicollet.com

Patrick James Flynn
Principal Investigator

Health Partners Inc

Patrick James Flynn
Ph: 952-993-1517
Email: MMCCOP@parknicollet.com

Patrick James Flynn
Principal Investigator

Hennepin County Medical Center

Patrick James Flynn
Ph: 952-993-1517
Email: MMCCOP@parknicollet.com

Patrick James Flynn
Principal Investigator

New Ulm

New Ulm Medical Center

Patrick James Flynn
Ph: 952-993-1517
Email: MMCCOP@parknicollet.com

Patrick James Flynn
Principal Investigator

Robbinsdale

North Memorial Medical Health Center

Patrick James Flynn
Ph: 952-993-1517
Email: MMCCOP@parknicollet.com

Patrick James Flynn
Principal Investigator

Rochester

Mayo Clinic

Ronald S. Go
Ph: 507-538-7623

Ronald S. Go
Principal Investigator

Saint Louis Park

Park Nicollet Clinic - Saint Louis Park

Patrick James Flynn
Ph: 952-993-1517
Email: MMCCOP@parknicollet.com

Patrick James Flynn
Principal Investigator

Saint Paul

Regions Hospital

Patrick James Flynn
Ph: 952-993-1517
Email: MMCCOP@parknicollet.com

Patrick James Flynn
Principal Investigator

United Hospital

Patrick James Flynn
Ph: 952-993-1517
Email: MMCCOP@parknicollet.com

Patrick James Flynn
Principal Investigator

Shakopee

Saint Francis Regional Medical Center

Patrick James Flynn
Ph: 952-993-1517
Email: MMCCOP@parknicollet.com

Patrick James Flynn
Principal Investigator

Stillwater

Lakeview Hospital

Patrick James Flynn
Ph: 952-993-1517
Email: MMCCOP@parknicollet.com

Patrick James Flynn
Principal Investigator

Waconia

Ridgeview Medical Center

Patrick James Flynn
Ph: 952-993-1517
Email: MMCCOP@parknicollet.com

Patrick James Flynn
Principal Investigator

Willmar

Rice Memorial Hospital

Patrick James Flynn
Ph: 952-993-1517
Email: MMCCOP@parknicollet.com

Patrick James Flynn
Principal Investigator

Woodbury

Minnesota Oncology and Hematology PA-Woodbury

Patrick James Flynn
Ph: 952-993-1517
Email: MMCCOP@parknicollet.com

Patrick James Flynn
Principal Investigator

Mississippi
Jackson

University of Mississippi Medical Center

Tondre T. Buck
Ph: 601-815-6700

Tondre T. Buck
Principal Investigator

Missouri
Bolivar

Central Care Cancer Center-Carrie J Babb Cancer Center

Jay W. Carlson
Ph: 800-821-7532

Jay W. Carlson
Principal Investigator

Bonne Terre

Parkland Health Center-Bonne Terre

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Branson

CoxHealth Cancer Center

Jay W. Carlson
Ph: 800-821-7532

Jay W. Carlson
Principal Investigator

Cape Girardeau

Saint Francis Medical Center

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Southeast Cancer Center

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Independence

Centerpoint Medical Center LLC

Rakesh Gaur
Ph: 913-948-5588
Email: aroland@kccop.org

Rakesh Gaur
Principal Investigator

Jefferson City

Capital Region Medical Center-Goldschmidt Cancer Center

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Kansas City

Heartland Hematology and Oncology Associates Incorporated

Rakesh Gaur
Ph: 913-948-5588
Email: aroland@kccop.org

Rakesh Gaur
Principal Investigator

Kansas City Cancer Center - South

Peter J. Van Veldhuizen
Ph: 800-525-1483

Peter J. Van Veldhuizen
Principal Investigator

Kansas City Cancer Centers - North

Peter J. Van Veldhuizen
Ph: 800-525-1483

Peter J. Van Veldhuizen
Principal Investigator

Research Medical Center

Rakesh Gaur
Ph: 913-948-5588
Email: aroland@kccop.org

Rakesh Gaur
Principal Investigator

Saint Luke's Hospital of Kansas City

Rakesh Gaur
Ph: 913-948-5588
Email: aroland@kccop.org

Rakesh Gaur
Principal Investigator

Truman Medical Center

Peter J. Van Veldhuizen
Ph: 800-525-1483

Peter J. Van Veldhuizen
Principal Investigator

Lee's Summit

Kansas City Cancer Center-Lee's Summit

Peter J. Van Veldhuizen
Ph: 800-525-1483

Peter J. Van Veldhuizen
Principal Investigator

Saint Luke's East - Lee's Summit

Rakesh Gaur
Ph: 913-948-5588
Email: aroland@kccop.org

Rakesh Gaur
Principal Investigator

Liberty

Liberty Radiation Oncology Center

Rakesh Gaur
Ph: 913-948-5588
Email: aroland@kccop.org

Rakesh Gaur
Principal Investigator

Rolla

Phelps County Regional Medical Center

Jay W. Carlson
Ph: 800-821-7532

Jay W. Carlson
Principal Investigator

Saint John's Clinic-Rolla-Cancer and Hematology

Jay W. Carlson
Ph: 800-821-7532

Jay W. Carlson
Principal Investigator

Saint Joseph

Heartland Regional Medical Center

Rakesh Gaur
Ph: 913-948-5588
Email: aroland@kccop.org

Rakesh Gaur
Principal Investigator

Saint Louis

Mercy Hospital Saint Louis

Jay W. Carlson
Ph: 800-821-7532

Jay W. Carlson
Principal Investigator

Missouri Baptist Medical Center

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Saint Louis Cancer and Breast Institute-South City

Jay W. Carlson
Ph: 800-821-7532

Jay W. Carlson
Principal Investigator

Sainte Genevieve

Sainte Genevieve County Memorial Hospital

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Springfield

CoxHealth South Hospital

Jay W. Carlson
Ph: 800-821-7532

Jay W. Carlson
Principal Investigator

Mercy Hospital Springfield

Jay W. Carlson
Ph: 800-821-7532

Jay W. Carlson
Principal Investigator

Sullivan

Missouri Baptist Sullivan Hospital

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Sunset Hills

Missouri Baptist Outpatient Center-Sunset Hills

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Nebraska
Lincoln

Nebraska Cancer Research Center

Gamini S. Soori
Ph: 402-991-8070ext202
Email: mwilwerding@mvcc.cc

Gamini S. Soori
Principal Investigator

Nebraska Hematology and Oncology

Gamini S. Soori
Ph: 402-991-8070ext202
Email: mwilwerding@mvcc.cc

Gamini S. Soori
Principal Investigator

Southeast Nebraska Cancer Center

Gamini S. Soori
Ph: 402-991-8070
Email: mwilwerding@mvcc.cc

Gamini S. Soori
Principal Investigator

Norfolk

Faith Regional Medical Offices West

Gamini S. Soori
Ph: 402-991-8070ext202
Email: mwilwerding@mvcc.cc

Gamini S. Soori
Principal Investigator

North Platte

Great Plains Regional Medical Center

Gamini S. Soori
Ph: 402-991-8070ext202
Email: mwilwerding@mvcc.cc

Gamini S. Soori
Principal Investigator

Omaha

Missouri Valley Cancer Consortium

Gamini S. Soori
Ph: 402-991-8070ext202
Email: mwilwerding@mvcc.cc

Gamini S. Soori
Principal Investigator

Oncology Hematology West

Gamini S. Soori
Ph: 402-991-8070ext202
Email: mwilwerding@mvcc.cc

Gamini S. Soori
Principal Investigator

Oncology Hematology West PC

Gamini S. Soori
Ph: 402-991-8070ext202
Email: mwilwerding@mvcc.cc

Gamini S. Soori
Principal Investigator

Scottsbluff

Regional West Medical Center

Gamini S. Soori
Ph: 402-991-8070ext202
Email: mwilwerding@mvcc.cc

Gamini S. Soori
Principal Investigator

Nevada
Henderson

21st Century Oncology - Henderson

John Allan Ellerton
Ph: 702-384-0013

John Allan Ellerton
Principal Investigator

Cancer and Blood Specialists-Henderson

John Allan Ellerton
Ph: 702-384-0013

John Allan Ellerton
Principal Investigator

Comprehensive Cancer Centers of Nevada - Henderson

John Allan Ellerton
Ph: 702-384-0013

John Allan Ellerton
Principal Investigator

Comprehensive Cancer Centers of Nevada-Southeast Henderson

John Allan Ellerton
Ph: 702-384-0013

John Allan Ellerton
Principal Investigator

Las Vegas Cancer Center-Henderson

John Allan Ellerton
Ph: 702-384-0013

John Allan Ellerton
Principal Investigator

Las Vegas

21st Century Oncology

John Allan Ellerton
Ph: 702-384-0013

John Allan Ellerton
Principal Investigator

21st Century Oncology - Fort Apache

John Allan Ellerton
Ph: 702-384-0013

John Allan Ellerton
Principal Investigator

21st Century Oncology - Vegas Tenaya

John Allan Ellerton
Ph: 702-384-0013

John Allan Ellerton
Principal Investigator

Cancer and Blood Specialists-Fort Apache

John Allan Ellerton
Ph: 702-384-0013

John Allan Ellerton
Principal Investigator

Cancer and Blood Specialists-Shadow

John Allan Ellerton
Ph: 702-384-0013

John Allan Ellerton
Principal Investigator

Cancer and Blood Specialists-Tenaya

John Allan Ellerton
Ph: 702-384-0013

John Allan Ellerton
Principal Investigator

Cancer Therapy and Integrative Medicine

John Allan Ellerton
Ph: 702-384-0013

John Allan Ellerton
Principal Investigator

Comprehensive Cancer Centers of Nevada

John Allan Ellerton
Ph: 702-384-0013

John Allan Ellerton
Principal Investigator

Comprehensive Cancer Centers of Nevada - Central Valley

John Allan Ellerton
Ph: 702-384-0013

John Allan Ellerton
Principal Investigator

Comprehensive Cancer Centers of Nevada - Northwest

John Allan Ellerton
Ph: 702-384-0013

John Allan Ellerton
Principal Investigator

Comprehensive Cancer Centers of Nevada-Summerlin

John Allan Ellerton
Ph: 702-384-0013

John Allan Ellerton
Principal Investigator

HealthCare Partners Medical Group Oncology/Hematology-Centennial Hills

John Allan Ellerton
Ph: 702-384-0013

John Allan Ellerton
Principal Investigator

HealthCare Partners Medical Group Oncology/Hematology-Maryland Parkway

John Allan Ellerton
Ph: 702-384-0013

John Allan Ellerton
Principal Investigator

HealthCare Partners Medical Group Oncology/Hematology-San Martin

John Allan Ellerton
Ph: 702-384-0013

John Allan Ellerton
Principal Investigator

HealthCare Partners Medical Group Oncology/Hematology-Tenaya

John Allan Ellerton
Ph: 702-384-0013

John Allan Ellerton
Principal Investigator

Las Vegas Cancer Center-Medical Center

John Allan Ellerton
Ph: 702-384-0013

John Allan Ellerton
Principal Investigator

Nevada Cancer Research Foundation CCOP

John Allan Ellerton
Ph: 702-384-0013

John Allan Ellerton
Principal Investigator

Radiation Oncology Centers of Nevada Central

John Allan Ellerton
Ph: 702-384-0013

John Allan Ellerton
Principal Investigator

Radiation Oncology Centers of Nevada Southeast

John Allan Ellerton
Ph: 702-384-0013

John Allan Ellerton
Principal Investigator

University Medical Center of Southern Nevada

John Allan Ellerton
Ph: 702-384-0013

John Allan Ellerton
Principal Investigator

New York
Rochester

University of Rochester

Jonathan Willmann Friedberg
Ph: 585-275-5830

Jonathan Willmann Friedberg
Principal Investigator

Staten Island

Staten Island University Hospital

Marcel Odaimi
Ph: 718-226-8888

Marcel Odaimi
Principal Investigator

North Carolina
Charlotte

Carolinas Medical Center/Levine Cancer Institute

Saad Zafar Usmani
Ph: 704-355-2884

Saad Zafar Usmani
Principal Investigator

Clinton

Southeastern Medical Oncology Center-Clinton

James N. Atkins
Ph: 919-580-0000

James N. Atkins
Principal Investigator

Concord

Carolinas Medical Center - Northeast

Saad Zafar Usmani
Ph: 704-355-2884

Saad Zafar Usmani
Principal Investigator

Goldsboro

Southeastern Medical Oncology Center-Goldsboro

James N. Atkins
Ph: 919-580-0000

James N. Atkins
Principal Investigator

Wayne Memorial Hospital

James N. Atkins
Ph: 919-580-0000

James N. Atkins
Principal Investigator

Jacksonville

Southeastern Medical Oncology Center-Jacksonville

James N. Atkins
Ph: 919-580-0000

James N. Atkins
Principal Investigator

Kinston

Kinston Medical Specialists PA

Peter Robins Watson
Ph: 252-559-2200

Peter Robins Watson
Principal Investigator

Monroe

Carolinas Medical Center-Union

Saad Zafar Usmani
Ph: 704-355-2884

Saad Zafar Usmani
Principal Investigator

Pinehurst

FirstHealth of the Carolinas-Moore Regional Hosiptal

Charles S. Kuzma
Ph: 910-715-2200

Charles S. Kuzma
Principal Investigator

Wilson

Southeastern Medical Oncology Center-Wilson

James N. Atkins
Ph: 919-580-0000

James N. Atkins
Principal Investigator

North Dakota
Bismarck

Sanford Bismarck Medical Center

Preston D. Steen
Ph: 701-234-6161

Preston D. Steen
Principal Investigator

Fargo

Roger Maris Cancer Center

Preston D. Steen
Ph: 701-234-6161

Preston D. Steen
Principal Investigator

Sanford Clinic North-Fargo

Preston D. Steen
Ph: 701-234-6161

Preston D. Steen
Principal Investigator

Sanford Medical Center-Fargo

Preston D. Steen
Ph: 701-234-6161

Preston D. Steen
Principal Investigator

Ohio
Akron

Summa Akron City Hospital/Cooper Cancer Center

Jennifer Eileen Payne
Ph: 330-375-6101

Jennifer Eileen Payne
Principal Investigator

Barberton

Summa Barberton Hospital

Jennifer Eileen Payne
Ph: 330-375-6101

Jennifer Eileen Payne
Principal Investigator

Beachwood

Cleveland Clinic Cancer Center Beachwood

Anjali S. Advani
Ph: 866-223-8100

Anjali S. Advani
Principal Investigator

Belpre

Strecker Cancer Center-Belpre

John Philip Kuebler
Ph: 614-566-3275

John Philip Kuebler
Principal Investigator

Centerville

Miami Valley Hospital South

Howard M. Gross
Ph: 937-775-1350

Howard M. Gross
Principal Investigator

Chillicothe

Adena Regional Medical Center

John Philip Kuebler
Ph: 614-566-3275

John Philip Kuebler
Principal Investigator

Cincinnati

Oncology Hematology Care Inc - Anderson

Howard M. Gross
Ph: 937-775-1350

Howard M. Gross
Principal Investigator

Oncology Hematology Care Inc - Kenwood

Howard M. Gross
Ph: 937-775-1350

Howard M. Gross
Principal Investigator

Oncology Hematology Care Inc-Blue Ash

Howard M. Gross
Ph: 937-775-1350

Howard M. Gross
Principal Investigator

Oncology Hematology Care Inc-Eden Park

Howard M. Gross
Ph: 937-775-1350

Howard M. Gross
Principal Investigator

Oncology Hematology Care Inc-Mercy West

Howard M. Gross
Ph: 937-775-1350

Howard M. Gross
Principal Investigator

Cleveland

Case Western Reserve University

Brenda Wimpfheimer Cooper
Ph: 800-641-2422

Brenda Wimpfheimer Cooper
Principal Investigator

Cleveland Clinic Cancer Center/Fairview Hospital

Anjali S. Advani
Ph: 866-223-8100

Anjali S. Advani
Principal Investigator

Cleveland Clinic Foundation

Anjali S. Advani
Ph: 866-223-8100

Anjali S. Advani
Principal Investigator

Columbus

Columbus Oncology and Hematology Associates Inc

John Philip Kuebler
Ph: 614-566-3275

John Philip Kuebler
Principal Investigator

Doctors Hospital

John Philip Kuebler
Ph: 614-566-3275

John Philip Kuebler
Principal Investigator

Grant Medical Center

John Philip Kuebler
Ph: 614-566-3275

John Philip Kuebler
Principal Investigator

Mount Carmel Health Center West

John Philip Kuebler
Ph: 614-566-3275

John Philip Kuebler
Principal Investigator

Riverside Methodist Hospital

John Philip Kuebler
Ph: 614-566-3275

John Philip Kuebler
Principal Investigator

The Mark H Zangmeister Center

John Philip Kuebler
Ph: 614-566-3275

John Philip Kuebler
Principal Investigator

Dayton

Good Samaritan Hospital - Dayton

Howard M. Gross
Ph: 937-775-1350

Howard M. Gross
Principal Investigator

Miami Valley Hospital

Howard M. Gross
Ph: 937-775-1350

Howard M. Gross
Principal Investigator

Samaritan North Health Center

Howard M. Gross
Ph: 937-775-1350

Howard M. Gross
Principal Investigator

Delaware

Delaware Health Center-Grady Cancer Center

John Philip Kuebler
Ph: 614-566-3275

John Philip Kuebler
Principal Investigator

Grady Memorial Hospital

John Philip Kuebler
Ph: 614-566-3275

John Philip Kuebler
Principal Investigator

Elyria

Mercy Cancer Center-Elyria

Brenda Wimpfheimer Cooper
Ph: 800-641-2422

Brenda Wimpfheimer Cooper
Principal Investigator

Fairfield

Oncology Hematology Care Inc-Healthplex

Howard M. Gross
Ph: 937-775-1350

Howard M. Gross
Principal Investigator

Findlay

Blanchard Valley Hospital

Howard M. Gross
Ph: 937-775-1350

Howard M. Gross
Principal Investigator

Franklin

Atrium Medical Center-Middletown Regional Hospital

Howard M. Gross
Ph: 937-775-1350

Howard M. Gross
Principal Investigator

Greenville

Wayne Hospital

Howard M. Gross
Ph: 937-775-1350

Howard M. Gross
Principal Investigator

Independence

Cleveland Clinic Cancer Center Independence

Anjali S. Advani
Ph: 866-223-8100

Anjali S. Advani
Principal Investigator

Kettering

Kettering Medical Center

Howard M. Gross
Ph: 937-775-1350

Howard M. Gross
Principal Investigator

Lancaster

Fairfield Medical Center

John Philip Kuebler
Ph: 614-566-3275

John Philip Kuebler
Principal Investigator

Mansfield

Cleveland Clinic Cancer Center Mansfield

Anjali S. Advani
Ph: 866-223-8100

Anjali S. Advani
Principal Investigator

Marietta

Marietta Memorial Hospital

John Philip Kuebler
Ph: 614-566-3275

John Philip Kuebler
Principal Investigator

Maumee

Toledo Clinic Cancer Centers-Maumee

Rex B. Mowat
Ph: 800-444-3561

Rex B. Mowat
Principal Investigator

Toledo Radiation Oncology at Northwest Ohio Onocolgy Center

Rex B. Mowat
Ph: 800-444-3561

Rex B. Mowat
Principal Investigator

Mayfield Heights

Hillcrest Hospital Cancer Center

Anjali S. Advani
Ph: 866-223-8100

Anjali S. Advani
Principal Investigator

Ireland Cancer Center Landerbrook Health Center

Brenda Wimpfheimer Cooper
Ph: 800-641-2422

Brenda Wimpfheimer Cooper
Principal Investigator

Medina

Summa Health Center at Lake Medina

Jennifer Eileen Payne
Ph: 330-375-6101

Jennifer Eileen Payne
Principal Investigator

Mentor

Lake University Ireland Cancer Center

Brenda Wimpfheimer Cooper
Ph: 800-641-2422

Brenda Wimpfheimer Cooper
Principal Investigator

Mount Vernon

Knox Community Hospital

John Philip Kuebler
Ph: 614-566-3275

John Philip Kuebler
Principal Investigator

Newark

Licking Memorial Hospital

John Philip Kuebler
Ph: 614-566-3275

John Philip Kuebler
Principal Investigator

Oregon

Saint Charles Hospital

Rex B. Mowat
Ph: 800-444-3561

Rex B. Mowat
Principal Investigator

Parma

University Hospitals Parma Medical Center

Brenda Wimpfheimer Cooper
Ph: 800-641-2422

Brenda Wimpfheimer Cooper
Principal Investigator

Portsmouth

Southern Ohio Medical Center

John Philip Kuebler
Ph: 614-566-3275

John Philip Kuebler
Principal Investigator

Sandusky

Ireland Cancer Center at Firelands Regional Medical Center

Brenda Wimpfheimer Cooper
Ph: 800-641-2422

Brenda Wimpfheimer Cooper
Principal Investigator

North Coast Cancer Care

Anjali S. Advani
Ph: 866-223-8100

Anjali S. Advani
Principal Investigator

Springfield

Springfield Regional Medical Center

John Philip Kuebler
Ph: 614-488-2745
Email: sheree@columbusccop.org

John Philip Kuebler
Principal Investigator

Strongsville

Cleveland Clinic Cancer Center Strongsville

Anjali S. Advani
Ph: 866-223-8100

Anjali S. Advani
Principal Investigator

Sylvania

Flower Hospital

Rex B. Mowat
Ph: 800-444-3561

Rex B. Mowat
Principal Investigator

Toledo

Mercy Saint Anne Hospital

Rex B. Mowat
Ph: 800-444-3561

Rex B. Mowat
Principal Investigator

Toledo Clinic Cancer Centers-Toledo

Rex B. Mowat
Ph: 800-444-3561

Rex B. Mowat
Principal Investigator

Toledo Community Hospital Oncology Program CCOP

Rex B. Mowat
Ph: 800-444-3561

Rex B. Mowat
Principal Investigator

University of Toledo

Rex B. Mowat
Ph: 800-444-3561

Rex B. Mowat
Principal Investigator

Troy

Upper Valley Medical Center

Howard M. Gross
Ph: 937-775-1350

Howard M. Gross
Principal Investigator

Warrensville Heights

South Pointe Hospital

Anjali S. Advani
Ph: 866-223-8100

Anjali S. Advani
Principal Investigator

Westerville

Saint Ann's Hospital

John Philip Kuebler
Ph: 614-566-3275

John Philip Kuebler
Principal Investigator

Wooster

Cleveland Clinic Wooster Specialty Center

Anjali S. Advani
Ph: 866-223-8100

Anjali S. Advani
Principal Investigator

Zanesville

Genesis HealthCare System

John Philip Kuebler
Ph: 614-488-2745
Email: sheree@columbusccop.org

John Philip Kuebler
Principal Investigator

Oklahoma
Oklahoma City

University of Oklahoma Health Sciences Center

George B. Selby
Ph: 405-271-4272
Email: julie-traylor@ouhsc.edu

George B. Selby
Principal Investigator

Oregon
Clackamas

Clackamas Radiation Oncology Center

Alison Katherine Conlin
Ph: 503-215-6412

Alison Katherine Conlin
Principal Investigator

Gresham

Legacy Mount Hood Medical Center

Jacqueline Vuky
Ph: 503-299-6500

Jacqueline Vuky
Principal Investigator

Newberg

Providence Newberg Medical Center

Alison Katherine Conlin
Ph: 503-215-6412

Alison Katherine Conlin
Principal Investigator

Oregon City

Providence Willamette Falls Medical Center

Alison Katherine Conlin
Ph: 503-215-6412

Alison Katherine Conlin
Principal Investigator

Portland

Legacy Good Samaritan Hospital and Medical Center

Jacqueline Vuky
Ph: 503-299-6500

Jacqueline Vuky
Principal Investigator

Providence Portland Medical Center

Alison Katherine Conlin
Ph: 503-215-6412

Alison Katherine Conlin
Principal Investigator

Providence Saint Vincent Medical Center

Alison Katherine Conlin
Ph: 503-215-6412

Alison Katherine Conlin
Principal Investigator

Tualatin

Legacy Meridian Park Hospital

Jacqueline Vuky
Ph: 503-299-6500

Jacqueline Vuky
Principal Investigator

Pennsylvania
Danville

Geisinger Medical Center

Edward J. Gorak
Ph: 570-271-5251

Edward J. Gorak
Principal Investigator

Hazleton

Geisinger Medical Center-Cancer Center Hazleton

Edward J. Gorak
Ph: 570-271-5251

Edward J. Gorak
Principal Investigator

Lewisburg

Geisinger Medical Oncology at Evangelical Community Hospital

Edward J. Gorak
Ph: 570-271-5251

Edward J. Gorak
Principal Investigator

Lewistown

Lewistown Hospital

Edward J. Gorak
Ph: 570-271-5251

Edward J. Gorak
Principal Investigator

Phoenixville

Phoenixville Hospital

Carl W. Sharer
Ph: 610-983-1908

Carl W. Sharer
Principal Investigator

Pottsville

Geisinger Medical Oncology-Pottsville

Edward J. Gorak
Ph: 570-271-5251

Edward J. Gorak
Principal Investigator

State College

Geisinger Medical Group

Edward J. Gorak
Ph: 570-271-5251

Edward J. Gorak
Principal Investigator

Wilkes-Barre

Geisinger Wyoming Valley/Henry Cancer Center

Edward J. Gorak
Ph: 570-271-5251

Edward J. Gorak
Principal Investigator

South Carolina
Charleston

Medical University of South Carolina

Saurabh Chhabra
Ph: 843-792-9321

Saurabh Chhabra
Principal Investigator

Florence

McLeod Regional Medical Center

Rajesh Bajaj
Ph: 843-679-7256

Rajesh Bajaj
Principal Investigator

South Dakota
Rapid City

Rapid City Regional Hospital

Mark Thomas Schroeder
Ph: 605-716-3982
Email: research@rcrh.org

Mark Thomas Schroeder
Principal Investigator

Texas
Houston

M D Anderson Cancer Center

Robert Zygmunt Orlowski
Ph: 713-792-3245

Robert Zygmunt Orlowski
Principal Investigator

Virginia
Martinsville

Memorial Hospital Of Martinsville

Sreedhar Katragadda
Ph: 276-666-7827

Sreedhar Katragadda
Principal Investigator

Washington
Longview

Saint John Medical Center

Alison Katherine Conlin
Ph: 503-215-6412

Alison Katherine Conlin
Principal Investigator

Vancouver

Compass Oncology Vancouver

Alison Katherine Conlin
Ph: 503-215-6412

Alison Katherine Conlin
Principal Investigator

Legacy Salmon Creek Hospital

Jacqueline Vuky
Ph: 503-299-6500

Jacqueline Vuky
Principal Investigator

PeaceHealth Southwest Medical Center

Alison Katherine Conlin
Ph: 503-215-6412

Alison Katherine Conlin
Principal Investigator

Wisconsin
Burlington

Aurora Cancer Care-Burlington

Dhimant R. Patel
Ph: 800-252-2990

Dhimant R. Patel
Principal Investigator

Chippewa Falls

Marshfield Clinic-Chippewa Center

Douglas J. Reding
Ph: 715-389-4457

Douglas J. Reding
Principal Investigator

Eau Claire

Marshfield Clinic Cancer Center at Sacred Heart

Douglas J. Reding
Ph: 715-389-4457

Douglas J. Reding
Principal Investigator

Elkhorn

Aurora Cancer Care-Southern Lakes

Dhimant R. Patel
Ph: 800-252-2990

Dhimant R. Patel
Principal Investigator

Fond Du Lac

Aurora Health Center-Fond du Lac

Dhimant R. Patel
Ph: 800-252-2990

Dhimant R. Patel
Principal Investigator

Grafton

Aurora Cancer Care-Grafton

Dhimant R. Patel
Ph: 800-252-2990

Dhimant R. Patel
Principal Investigator

Green Bay

Aurora BayCare Medical Center

Dhimant R. Patel
Ph: 800-252-2990

Dhimant R. Patel
Principal Investigator

Green Bay Oncology at Saint Vincent Hospital

Matthew L. Ryan
Ph: 800-432-6049

Matthew L. Ryan
Principal Investigator

Green Bay Oncology Limited at Saint Mary's Hospital

Matthew L. Ryan
Ph: 800-432-6049

Matthew L. Ryan
Principal Investigator

Saint Mary's Hospital

Matthew L. Ryan
Ph: 800-432-6049

Matthew L. Ryan
Principal Investigator

Saint Vincent Hospital

Matthew L. Ryan
Ph: 800-432-6049

Matthew L. Ryan
Principal Investigator

Kenosha

Aurora Cancer Care-Kenosha South

Dhimant R. Patel
Ph: 800-252-2990

Dhimant R. Patel
Principal Investigator

La Crosse

Gundersen Lutheran Medical Center

Kurt Oettel
Ph: 608-775-2385
Email: cancerctr@gundluth.org

Kurt Oettel
Principal Investigator

Madison

University of Wisconsin Hospital and Clinics

Natalie Scott Callander
Ph: 877-405-6866

Natalie Scott Callander
Principal Investigator

Manitowoc

Holy Family Memorial Hospital

Matthew L. Ryan
Ph: 800-432-6049

Matthew L. Ryan
Principal Investigator

Marinette

Bay Area Medical Center

Matthew L. Ryan
Ph: 800-432-6049

Matthew L. Ryan
Principal Investigator

Vince Lombardi Cancer Clinic-Marinette

Dhimant R. Patel
Ph: 800-252-2990

Dhimant R. Patel
Principal Investigator

Marshfield

Marshfield Clinic

Douglas J. Reding
Ph: 715-389-4457

Douglas J. Reding
Principal Investigator

Menomonee Falls

Aurora Advanced Healthcare Inc-Menomonee Falls

Dhimant R. Patel
Ph: 800-252-2990

Dhimant R. Patel
Principal Investigator

Milwaukee

Aurora Cancer Care-Milwaukee

Dhimant R. Patel
Ph: 800-252-2990

Dhimant R. Patel
Principal Investigator

Aurora Saint Luke's Medical Center

Dhimant R. Patel
Ph: 800-252-2990

Dhimant R. Patel
Principal Investigator

Aurora Sinai Medical Center

Dhimant R. Patel
Ph: 800-252-2990

Dhimant R. Patel
Principal Investigator

Minocqua

Marshfield Clinic-Minocqua Center

Douglas J. Reding
Ph: 715-389-4457

Douglas J. Reding
Principal Investigator

New Richmond

Cancer Center of Western Wisconsin

Patrick James Flynn
Ph: 952-993-1517
Email: MMCCOP@parknicollet.com

Patrick James Flynn
Principal Investigator

Oconto Falls

Green Bay Oncology - Oconto Falls

Matthew L. Ryan
Ph: 800-432-6049

Matthew L. Ryan
Principal Investigator

Oshkosh

Vince Lombardi Cancer Clinic - Oshkosh

Dhimant R. Patel
Ph: 800-252-2990

Dhimant R. Patel
Principal Investigator

Racine

Aurora Cancer Care-Racine

Dhimant R. Patel
Ph: 800-252-2990

Dhimant R. Patel
Principal Investigator

Rhinelander

Marshfield Clinic at James Beck Cancer Center

Douglas J. Reding
Ph: 715-389-4457

Douglas J. Reding
Principal Investigator

Rice Lake

Lakeview Medical Center-Marshfield Clinic

Douglas J. Reding
Ph: 715-389-4457

Douglas J. Reding
Principal Investigator

Marshfield Clinic-Rice Lake Center

Douglas J. Reding
Ph: 715-389-4457

Douglas J. Reding
Principal Investigator

Sheboygan

Saint Nicholas Hospital

Matthew L. Ryan
Ph: 800-432-6049

Matthew L. Ryan
Principal Investigator

Vince Lombardi Cancer Clinic-Sheboygan

Dhimant R. Patel
Ph: 800-252-2990

Dhimant R. Patel
Principal Investigator

Stevens Point

Marshfield Clinic Cancer Care at Saint Michael's Hospital

Douglas J. Reding
Ph: 715-389-4457

Douglas J. Reding
Principal Investigator

Sturgeon Bay

Green Bay Oncology - Sturgeon Bay

Matthew L. Ryan
Ph: 800-432-6049

Matthew L. Ryan
Principal Investigator

Summit

Aurora Medical Center in Summit

Dhimant R. Patel
Ph: 800-252-2990

Dhimant R. Patel
Principal Investigator

Two Rivers

Vince Lombardi Cancer Clinic

Dhimant R. Patel
Ph: 800-252-2990

Dhimant R. Patel
Principal Investigator

Waukesha

Aurora Cancer Care-Waukesha

Dhimant R. Patel
Ph: 800-252-2990

Dhimant R. Patel
Principal Investigator

Wausau

Marshfield Clinic-Wausau Center

Douglas J. Reding
Ph: 715-389-4457

Douglas J. Reding
Principal Investigator

Wauwatosa

Aurora Cancer Care-Milwaukee West

Dhimant R. Patel
Ph: 800-252-2990

Dhimant R. Patel
Principal Investigator

West Allis

Aurora West Allis Medical Center

Dhimant R. Patel
Ph: 800-252-2990

Dhimant R. Patel
Principal Investigator

Weston

Diagnostic and Treatment Center

Douglas J. Reding
Ph: 715-389-4457

Douglas J. Reding
Principal Investigator

Marshfield Clinic - Weston Center

Douglas J. Reding
Ph: 715-389-4457

Douglas J. Reding
Principal Investigator

Wisconsin Rapids

Marshfield Clinic - Wisconsin Rapids Center

Douglas J. Reding
Ph: 715-389-4457

Douglas J. Reding
Principal Investigator

Link to the current ClinicalTrials.gov record.
NLM Identifer NCT01668719

Note: Information about participating sites on pharmaceutical industry trials may be incomplete. Please visit the ClinicalTrials.gov record via the link above for more information about participating sites.